Kivu Bioscience

Thanks Nasdaq for celebrating our $92M Series A funding led by Novo Holdings to develop next-generation ADC therapies that are potentially more effective and safer for cancer patients. ???? The round also included participation from Gimv, Red Tree Venture Capital, HealthCap as well as existing investors BGV (BioGeneration Ventures), M Ventures and Brabantse Ontwikkelings Maatschappij (BOM) - thanks to all for your support. Read our release: ?? https://lnkd.in/eHudVNKA Endpoints News: ?? https://lnkd.in/ep8aDTTz BioPharma Dive: ?? https://lnkd.in/eFF6yVbT FirstWord Pharma: ?? https://lnkd.in/emw36yHm

Thanks NYSE for this iconic floor takeover with our recent $92M Series A funding news led by Novo Holdings. ???? We are inspired by patients and driven by data to accelerate transformative medicines in oncology. Kivu’s assets are in late-stage preclinical studies and target areas of high unmet medical need. The company’s platform is differentiated by its superior ability to avoid the issues seen with currently marketed ADCs and addresses key limitations related to stability and therapeutic precision and delivery. Press release: ?? https://lnkd.in/eHudVNKA Endpoints News : ?? https://lnkd.in/ep8aDTTz BioPharma Dive: ?? https://lnkd.in/eFF6yVbT MedCity News: ?? https://lnkd.in/gX_Tp7qm BioCentury Inc. : ?? https://lnkd.in/eP4wb68B FirstWord Pharma: ?? https://lnkd.in/emw36yHm The Pharma Letter: ?? https://lnkd.in/eY5SYkMp Pharmaceutical Business Review: ?? https://lnkd.in/eEqRAKV5

Thanks MedCity News senior biopharma reporter Frank Vinluan for speaking with our President & COO Mohit Trikha. "It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said Mohit Trikha, president and chief operating officer of Kivu Bioscience. Kivu is developing therapies intended to offer better tolerability and efficacy. The startup emerged from stealth this week,?revealing $92 million?in financing and plans to bring its lead program into the clinic in 2025. San Francisco-based Kivu is developing antibody drug conjugates (ADCs), a type of drug comprised of a targeting antibody linked to a potent cancer-killing payload. While the ability to deliver a powerful, targeted strike to cancer cells has made this class of drugs a hot area of research and dealmaking, ADCs still have limitations, Trikha said. Sometimes the toxic drug payload falls off the antibody, leading to adverse effects elsewhere in the body. Severe lung and eye toxicity are known complications of currently available ADCs. Off-target toxicity happens when an ADC is unstable, said Trikha, whose 25 years of experience in cancer research includes serving as an oncology executive at AbbVie. Kivu aims to improve stability with technology licensed from Synaffix, an Amsterdam-based company whose ADC technologies are used by many biotech companies. Last year, contract drug and manufacturing organization giant?Lonza acquired Synaffix?for €100 million (about $107 million) up front in a move to strengthen its ADC service offerings to its customers. In my mind, precision oncology is bringing the right drug to the right patient at the right time, with the right schedule,” Trikha said. “Cancer medicines, whether it’s an ADC or something else, has a benefit to risk profile. Not only do we want to have efficacious drugs, we want to reduce toxicity, improve tolerability, so patients stay on treatment. Kivu aims for each of its drugs to achieve single-agent activity. That’s important because with combination treatments, patients often reduce dosing to manage the regimen’s toxic effects, Trikha said." Read the article: https://lnkd.in/gX_Tp7qm

Mohit Trikha our President and COO speaks with BioPharma Dive: https://lnkd.in/eFF6yVbT

FirstWord Pharma covers our recent $92M Series A led by Novo Holdings: Stability and safety Kivu's two-part goal is simple: achieve the highest ADC concentration possible within the tumour microenvironment, while minimising dose reductions and treatment interruptions. "This is why you'll hear me say that, at Kivu, we're excited to develop kinder, gentler ADCs, because we want to keep patients on treatment for a longer period of time," said Trikha, who serves as the startup's chief operating officer and president. "We want efficacy, but another way to deepen efficacy and achieve deeper responses is by decreasing the toxicity and increasing patient quality of life." Read the article: https://lnkd.in/emw36yHm

Our President and COO Mohit Trikha spoke with Endpoints News for the company launch. “In the race to create next-gen ADCs, Kivu said it hopes to make Topo1i-based medicines that are more durable, can be dosed higher and have less toxic impact on healthy parts of the body. The startup said it anticipates entering human trials with its first solid tumor ADC, codenamed KIVU-107, next year.” Read the article by Kyle LaHucik: https://lnkd.in/ep8aDTTz

The Novo Holdings Venture Investments team led a $92 million Series A Financing in Kivu Bioscience, an early-stage biotech company developing next-generation antibody-drug conjugate (ADC) programs to deliver therapies that are more effective and safer for cancer patients. The funding will be used to advance Kivu’s multiple oncology programs, including its Topo1i-based ADC pipeline, which is set to begin Phase 1 trials in 2025. ? Learn more about Kivu here: https://lnkd.in/eauA6crw #ventureinvestments #biotech #ADC

We are excited to announce the official launch of Kivu Bioscience with a $92M Series A led by Novo Holdings with participation from Gimv, Red Tree Venture Capital, HealthCap as well as existing investors BGV (BioGeneration Ventures), M Ventures , and Brabantse Ontwikkelings Maatschappij (BOM). The funding will be used to advance multiple oncology programs focused on next-gen ADC therapies into the clinic. Sharing the press release: https://lnkd.in/gexBkmbD